Cartesian Therapeutics, Inc. (RNAC) Balance Sheet

The consistent expansion of the accumulated deficit suggests that the company is consuming its capital base to fund R&D without generating offsetting value. This trajectory indicates that the firm is increasingly reliant on external financing to maintain operations, which may lead to further shareholder dilution.

While the current ratio of 7.65 appears robust on the surface, it is largely a function of the company's specific liability structure rather than operational efficiency. Investors should monitor the rate of cash depletion, as the current burn rate may necessitate additional capital raises in the near term.

The asset mix is heavily skewed toward intangible assets and cash, confirming an asset-light model that is entirely dependent on the success of the Descartes-08 program. Any failure to achieve clinical milestones could necessitate a write-down of these intangibles, further pressuring the already negative equity position.